<DOC>
	<DOCNO>NCT01284569</DOCNO>
	<brief_summary>The purpose study determine whether ALX-0061 , Nanobody target receptor interleukin 6 ( IL6R ) , safe effective single multiple administration patient rheumatoid arthritis ( RA ) . Patients receive different single multiple dose either placebo ALX-0061 .</brief_summary>
	<brief_title>Study Assess Safety Efficacy Anti-Interleukin 6-receptor ( IL6R ) Nanobody Rheumatoid Arthritis ( RA ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Body mass index ( BMI ) &lt; 35.0 kg/m2 Diagnosed rheumatoid arthritis ( RA ) accord 2010 European League Against Rheumatism ( EULAR ) / American College Rheumatology ( ACR ) criteria least 6 month prior randomisation Treatment methotrexate ( MTX ) least 12 week prior screen , least 4 week screen stable dose , remain stable throughout study period . Inadequate response intolerance disease modify antirheumatic drug ( DMARDs ) ( include MTX , patient may remain treatment % TX low dose improve tolerance , reduce effectiveness ) For patient ( men woman ) reproductive potential , use acceptable method contraception duration study . Female patient must willing use appropriate birth control measure would prevent pregnancy start time signing inform consent 90 day last dose study drug administer For single dose part : Disease Activity Score use 28 joint count ( DAS28 ) score &gt; = 2.4 For multiple dose part : DAS28 score &gt; = 3.2 For multiple dose part : swollen joint count &gt; = 3 A documented history autoimmune disease RA ( secondary Sj√∂gren 's syndrome ) Functional class IV ACR classification Any new/additional biologic DMARD therapy , cytotoxic drug immunosuppressant within four week prior screen , screen Day 1 exception ALX0061 Suspicion active tuberculosis verify quantiferon test abnormal chest Xray Female patient pregnant study , breastfeed History anaphylactic reaction protein therapeutic Participation investigational drug study within 60 day prior drug administration except patient participate single dose part study eligible participate multiple dose part Donation 300 mL blood within 60 day prior drug administration Malignancy , prior malignancy , disease free interval &lt; 5 year diagnosis intervention except curative treatment nonmelanoma skin cancer resect carcinoma situ Any current recent ( within 4 week prior first dose ) sign symptoms infection require parenteral antibiotic administration , know active viral infection ( hepatitis B virus [ HBV ] , hepatitis C virus [ HCV ] , human immunodeficiency virus [ HIV ] ) would impair participation study Major surgery ( include joint surgery ) within 8 week prior screen hospitalisation clinically relevant event within 4 week prior screen Any disease , metabolic dysfunction , physical examination finding , clinically significant laboratory find give reasonable suspicion disease condition contraindicate use investigational drug may affect interpretation result render patient high risk treatment complication Administration live , attenuated vaccine within 1 month dose ALX0061 , anticipation live attenuated vaccine require study within 60 day last dose For multiple dose part : contraindication MRIs use contrast agent MRI scan</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>